Succinobucol No Help for Acute Coronary Syndrome Outcomes

Cardiovascular outcomes no better but the drug has other positive and negative effects

TUESDAY, May 27 (HealthDay News) -- The antioxidant succinobucol has no impact on cardiovascular outcomes for patients with acute coronary syndrome but it has a positive impact on new-onset diabetes and a negative impact on new-onset atrial fibrillation as well as bleeding episodes and anemia, according to study findings published in the May 24 issue of The Lancet.

Jean-Claude Tardif, M.D., of the University of Montreal in Canada, and colleagues conducted a study of 6,144 patients who were recruited 14 to 365 days after an acute coronary syndrome, of whom 3,078 were randomized to receive succinobucol and 3,066 to receive placebo as well as standard of care. The trial ran from July 2003 until the prespecified number of primary outcome events had occurred, in August 2006.

There was no effect on the composite primary endpoint, i.e., time to first occurrence of cardiovascular death, resuscitated cardiac arrest, coronary revascularization, myocardial infarction, unstable angina or stroke, which occurred 530 times in the succinobucol group and 529 times in the placebo group.

"Although succinobucol had no effect on the primary endpoint, changes in the rates of other clinical outcomes -- both beneficial and harmful -- will need to be further assessed before succinobucol is used in patients with atherosclerosis or as an antidiabetic agent," the authors conclude.

Full Text (subscription or payment may be required)

Physician's Briefing